JP2019534251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534251A5 JP2019534251A5 JP2019516622A JP2019516622A JP2019534251A5 JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5 JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- taxane
- body surface
- surface area
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401638P | 2016-09-29 | 2016-09-29 | |
| US62/401,638 | 2016-09-29 | ||
| PCT/US2017/053954 WO2018064299A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534251A JP2019534251A (ja) | 2019-11-28 |
| JP2019534251A5 true JP2019534251A5 (https=) | 2020-11-12 |
Family
ID=60186360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516622A Pending JP2019534251A (ja) | 2016-09-29 | 2017-09-28 | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209701A1 (https=) |
| EP (1) | EP3518970A1 (https=) |
| JP (1) | JP2019534251A (https=) |
| KR (1) | KR20190061030A (https=) |
| CN (1) | CN109862917A (https=) |
| AU (1) | AU2017335839A1 (https=) |
| BR (1) | BR112019005815A2 (https=) |
| CA (1) | CA3038671A1 (https=) |
| IL (1) | IL265668A (https=) |
| MX (1) | MX2019003603A (https=) |
| TW (1) | TW201815419A (https=) |
| WO (1) | WO2018064299A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102689256B1 (ko) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
| KR102739487B1 (ko) * | 2018-09-21 | 2024-12-10 | 제넨테크, 인크. | 3중-음성 유방암에 대한 진단 방법 |
| JP2022504905A (ja) * | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷 |
| TWI719765B (zh) * | 2018-12-19 | 2021-02-21 | 美商建南德克公司 | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 |
| AU2021293038A1 (en) * | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| MX368257B (es) * | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| KR20190057421A (ko) | 2012-08-17 | 2019-05-28 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| KR102204520B1 (ko) | 2012-10-12 | 2021-01-20 | 엑셀리시스, 인코포레이티드 | 암의 치료에 사용하기 위한 화합물의 신규 제조 방법 |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR102689256B1 (ko) * | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
-
2017
- 2017-09-28 AU AU2017335839A patent/AU2017335839A1/en not_active Abandoned
- 2017-09-28 TW TW106133384A patent/TW201815419A/zh unknown
- 2017-09-28 BR BR112019005815A patent/BR112019005815A2/pt not_active Application Discontinuation
- 2017-09-28 CN CN201780065799.4A patent/CN109862917A/zh active Pending
- 2017-09-28 MX MX2019003603A patent/MX2019003603A/es unknown
- 2017-09-28 KR KR1020197011867A patent/KR20190061030A/ko not_active Ceased
- 2017-09-28 WO PCT/US2017/053954 patent/WO2018064299A1/en not_active Ceased
- 2017-09-28 EP EP17791212.8A patent/EP3518970A1/en not_active Withdrawn
- 2017-09-28 CA CA3038671A patent/CA3038671A1/en not_active Abandoned
- 2017-09-28 JP JP2019516622A patent/JP2019534251A/ja active Pending
-
2019
- 2019-03-27 US US16/366,411 patent/US20190209701A1/en not_active Abandoned
- 2019-03-27 IL IL265668A patent/IL265668A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534251A5 (https=) | ||
| JP2018108086A5 (https=) | ||
| JP2018184417A5 (https=) | ||
| JP2019524820A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| JP2012525853A5 (https=) | ||
| JP2015527318A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| IL300151A (en) | Combinations for cancer treatment | |
| JP2015529225A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2015530867A5 (https=) | ||
| JP2016503413A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| RU2015151454A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АФУКОЗИЛИРОВАННОГО АНТИТЕЛА К CD20 В СОЧЕТАНИИ С КОНЪЮГАТОМ АНТИТЕЛО К CD79b-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018530578A5 (https=) | ||
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| JP2024533067A5 (https=) | ||
| JP2018529661A5 (https=) | ||
| JP2018522028A5 (https=) | ||
| RU2016128223A (ru) | Лечение вируса гриппа а h7n9 | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний |